A newly revealed molecular tug-of-war may have implications for better understanding how a multitude of diseases and ...

What keeps our cells the right size? Scientists have long puzzled over this fundamental question, since cells that are too ...

Researchers at the Icahn School of Medicine at Mount Sinai have developed a first-of-its-kind mRNA system that switches on ...

A nucleoside-modified mRNA (modRNA) influenza vaccine showed greater protection against influenza-like illness compared to a standard inactivated vaccine in adults. 2. The modRNA vaccine triggered ...

The modRNA vaccine had superior relative efficacy against influenza-like illness, but more reactogenicity events. HealthDay News — A quadrivalent nucleoside-modified messenger RNA (modRNA) influenza ...

(HealthDay News) — A quadrivalent nucleoside-modified messenger RNA (modRNA) influenza vaccine is superior to a licensed inactivated quadrivalent influenza vaccine, according to a study published in ...

Researchers found that the relative efficacy of the modRNA vaccine was 34.5% against influenza-like illness compared with the control vaccine, on the basis of 57 and 87 cases in the modRNA and control ...

In this randomized Phase III trial, investigators assigned 18,476 healthy adults between 18 and 64 years of age to receive either a quadrivalent modified mRNA influenza vaccine or a licensed ...

The "mRNA Vaccines Market - Global Forecast 2025-2032" has been added to ResearchAndMarkets.com's offering. The mRNA Vaccines Market is experiencing significant growth, evolving from USD 9.32 billion ...

Moderna Inc (NASDAQ:MRNA) stock is trading sharply lower on Monday afternoon as recent clinical setbacks overshadowed positive pipeline news. What To Know: The decline continues despite Moderna’s ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower on Friday afternoon, giving back a portion of the gains seen on Thursday. Here’s what investors need to know. What To Know: The stock spiked on ...